Literature DB >> 34987232

Neurogenetic disorders across the lifespan: from aberrant development to degeneration.

Richard A Hickman1, Sarah A O'Shea2, Mark F Mehler3,4,5, Wendy K Chung6,7.   

Abstract

Intellectual disability and autism spectrum disorder (ASD) are common, and genetic testing is increasingly performed in individuals with these diagnoses to inform prognosis, refine management and provide information about recurrence risk in the family. For neurogenetic conditions associated with intellectual disability and ASD, data on natural history in adults are scarce; however, as older adults with these disorders are identified, it is becoming clear that some conditions are associated with both neurodevelopmental problems and neurodegeneration. Moreover, emerging evidence indicates that some neurogenetic conditions associated primarily with neurodegeneration also affect neurodevelopment. In this Perspective, we discuss examples of diseases that have developmental and degenerative overlap. We propose that neurogenetic disorders should be studied continually across the lifespan to understand the roles of the affected genes in brain development and maintenance, and to inform strategies for treatment.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 34987232     DOI: 10.1038/s41582-021-00595-5

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  161 in total

Review 1.  Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  D J Michelson; M I Shevell; E H Sherr; J B Moeschler; A L Gropman; S Ashwal
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

2.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

3.  The pathological association between Down syndrome and Alzheimer disease.

Authors:  D M Mann
Journal:  Mech Ageing Dev       Date:  1988-05       Impact factor: 5.432

4.  Life expectancy of people with intellectual disability: a 35-year follow-up study.

Authors:  K Patja; M Iivanainen; H Vesala; H Oksanen; I Ruoppila
Journal:  J Intellect Disabil Res       Date:  2000-10

Review 5.  Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.

Authors:  Richard A Hickman; Arline Faustin; Thomas Wisniewski
Journal:  Neurol Clin       Date:  2016-08-04       Impact factor: 3.806

6.  Down syndrome and Alzheimer's disease: Common pathways, common goals.

Authors:  Dean Hartley; Thomas Blumenthal; Maria Carrillo; Gilbert DiPaolo; Lucille Esralew; Katheleen Gardiner; Ann-Charlotte Granholm; Khalid Iqbal; Michael Krams; Cynthia Lemere; Ira Lott; William Mobley; Seth Ness; Ralph Nixon; Huntington Potter; Roger Reeves; Marwan Sabbagh; Wayne Silverman; Benjamin Tycko; Michelle Whitten; Thomas Wisniewski
Journal:  Alzheimers Dement       Date:  2014-12-12       Impact factor: 21.566

7.  Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis.

Authors:  J B Leverenz; M A Raskind
Journal:  Exp Neurol       Date:  1998-04       Impact factor: 5.330

8.  Mortality in adults with moderate to profound intellectual disability: a population-based study.

Authors:  F Tyrer; L K Smith; C W McGrother
Journal:  J Intellect Disabil Res       Date:  2007-07

Review 9.  People with intellectual disability: what do we know about adulthood and life expectancy?

Authors:  A M W Coppus
Journal:  Dev Disabil Res Rev       Date:  2013

10.  Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016.

Authors:  Matthew J Maenner; Kelly A Shaw; Jon Baio; Anita Washington; Mary Patrick; Monica DiRienzo; Deborah L Christensen; Lisa D Wiggins; Sydney Pettygrove; Jennifer G Andrews; Maya Lopez; Allison Hudson; Thaer Baroud; Yvette Schwenk; Tiffany White; Cordelia Robinson Rosenberg; Li-Ching Lee; Rebecca A Harrington; Margaret Huston; Amy Hewitt; Amy Esler; Jennifer Hall-Lande; Jenny N Poynter; Libby Hallas-Muchow; John N Constantino; Robert T Fitzgerald; Walter Zahorodny; Josephine Shenouda; Julie L Daniels; Zachary Warren; Alison Vehorn; Angelica Salinas; Maureen S Durkin; Patricia M Dietz
Journal:  MMWR Surveill Summ       Date:  2020-03-27
View more
  4 in total

1.  Autistic-like behavior and cerebellar dysfunction in Bmal1 mutant mice ameliorated by mTORC1 inhibition.

Authors:  Dong Liu; Carmen Nanclares; Konstanze Simbriger; Kun Fang; Ethan Lorsung; Nam Le; Inês Silva Amorim; Kleanthi Chalkiadaki; Salil Saurav Pathak; Jin Li; Jonathan C Gewirtz; Victor X Jin; Paulo Kofuji; Alfonso Araque; Harry T Orr; Christos G Gkogkas; Ruifeng Cao
Journal:  Mol Psychiatry       Date:  2022-03-17       Impact factor: 13.437

Review 2.  Steroid Sulfation in Neurodegenerative Diseases.

Authors:  Jana Vitku; Martin Hill; Lucie Kolatorova; Eva Kubala Havrdova; Radmila Kancheva
Journal:  Front Mol Biosci       Date:  2022-02-23

3.  The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade.

Authors:  Richard A Hickman; Phyllis L Faust; Karen Marder; Ai Yamamoto; Jean-Paul Vonsattel
Journal:  Acta Neuropathol Commun       Date:  2022-04-19       Impact factor: 7.578

4.  The Atypical Effective Connectivity of Right Temporoparietal Junction in Autism Spectrum Disorder: A Multi-Site Study.

Authors:  Zeqi Hao; Yuyu Shi; Lina Huang; Jiawei Sun; Mengting Li; Yanyan Gao; Jing Li; Qianqian Wang; Linlin Zhan; Qingguo Ding; Xize Jia; Huayun Li
Journal:  Front Neurosci       Date:  2022-07-18       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.